<code id='407612A721'></code><style id='407612A721'></style>
      • <acronym id='407612A721'></acronym>
      <center id='407612A721'><center id='407612A721'><tfoot id='407612A721'></tfoot></center><abbr id='407612A721'><dir id='407612A721'><tfoot id='407612A721'></tfoot><noframes id='407612A721'>
      • <optgroup id='407612A721'><strike id='407612A721'><sup id='407612A721'></sup></strike><code id='407612A721'></code></optgroup>
        5. <b id='407612A721'><label id='407612A721'><select id='407612A721'><dt id='407612A721'><span id='407612A721'></span></dt></select></label></b><u id='407612A721'></u>
          <i id='407612A721'><strike id='407612A721'><tt id='407612A721'><pre id='407612A721'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / hotspot      
           
     
           
      
          hotspot 
           
      
           
      
           
       2025-09-27 13:42:45 
   
      
           
      
           
                        
          hotspot  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：8667
                                  
                                    
          
                                   
          Rachel Haurwitz of Caribou Biosciences
          Rachel Haurwitz, CEO of Caribou Biosciences.																									Elizabeth D. Herman for STAT
          Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.
          In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.
          advertisement
          The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.
          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!					
          GET STARTED													Log In											
                      
                              
          
                                 Previous article：

                                
                                          Readout LOUD podcast: Merger Mondays, Ozempic panic
                                
                            
          Next article：  
                                      
                                          Duchenne breakthrough therapy leaves behind pioneering families
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles